BIOCEPT, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-11-13: Form 8-K; Period of report 2014-11-13; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2014-07-24: Form 8-K; Period of report 2014-07-21; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2014-06-18: Form 8-K; Period of report 2014-06-12; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; Details 5.02.
- 2014-05-23: Form 8-K; Period of report 2014-05-19; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-11-13 | 8-K | 2014-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2014, we issued a press release announcing our financial results for the third quarter of 2014. | bioc-8k_20140930.htm |
| 2014-07-24 | 8-K | 2014-07-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 21, 2014, Farideh Z. Bischoff, Ph.D., notified the Company of her intent to resign as Vice-President Translational Research and Clinical Development of Biocept, Inc. (the “Company”), to be effective on August 12, 2014. | d764175d8k.htm |
| 2014-06-18 | 8-K | 2014-06-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On June 12, 2014, with the recommendation of the Compensation Committee (the “Committee”) of the Board of Directors of Biocept, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) approved the issuance of 44,496 restricted stock units, or RSUs, of the Company to its Chief Executive Officer, Michael Nall, pursuant to its 2013 Equity Incentive Plan. 5.07 The Company held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 12, 2014 at the Company’s corporate headquarters located at 5810 Nancy Ridge Drive, San Diego, California 92121. | d745116d8k.htm |
| 2014-05-23 | 8-K | 2014-05-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 19, 2014, the Compensation Committee of the Board of Directors (the “Committee”) of Biocept, Inc. (the “Company”) approved the Annual Incentive Plan (the “Annual Incentive Plan”). | d731946d8k.htm |
| 2014-05-06 | 8-K | 2014-04-30 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 Effective as of April 30, 2014 (the “closing date”), we entered into a loan and security agreement (the “credit facility”) with Oxford Finance LLC (“Oxford”), as collateral agent, and the lenders party thereto from time to time (the “Lenders”), including Oxford, pursuant to which the Lenders agreed to make term loans available to us for working capital and general business purposes, in a principal amount of up to $10 million. 3.02 The warrants described in Item 2.03 above were offered and sold in reliance upon the exemption from registration provided by Section 4(2) under the Securities Act of 1933 (the “Securities Act”). | d719738d8k.htm |
| 2014-03-17 | 8-K | 2014-03-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Executive Compensation; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | d695557d8k.htm |
| 2014-02-14 | 8-K | 2014-02-10 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 5.02 Executive Compensation; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 8.01 Pursuant to an Underwriting Agreement dated February 4, 2014 between us and Aegis Capital Corp., as representative of the several underwriters named therein, we effected an initial public offering of 1,900,000 shares of common stock at $10.00 per share on February 5, 2014. | d676837d8k.htm |